The Dietary Supplement Industry in the Time of Trump: Potential Opportunities and Pitfalls

FDLI Update November/December 2017

Theodora McCormick, a Member of the Firm in the Litigation and Health Care and Life Sciences practices, in the firm’s Princeton and Newark offices, authored an article in Food and Drug Law Institute (FDLI) Update, titled “The Dietary Supplement Industry in the Time of Trump: Potential Opportunities and Pitfalls.”

Following is an excerpt (see below to download the full article in PDF format):

The new administration came into office promising to loosen the regulatory environment for business and ease the burdens to sale, positioning, and marketing of consumer products. While this presents a great opportunity for the dietary supplement industry in the form of less regulation and less enforcement, there are also many potential pitfalls such as tainted products, blatant GMP violations, and fraudulent marketing. Whether a so-called “regulatory holiday” is a golden ticket or impending disaster remains to be seen. Some of the possible risks and opportunities are outlined below, along with proactive steps industry members can and should take in order to take advantage of this new world order.

Resources